Benzinga | Nov 22, 2021 04:03PM EST

Enanta Pharmaceuticals Q4 EPS $(1.22), Inline, Sales $23.60M Miss $26.34M Estimate

Enanta Pharmaceuticals (NASDAQ:ENTA) reported quarterly losses of $(1.22) per share which met the analyst consensus estimate. This is a 16.44 percent increase over losses of $(1.46) per share from the same period last year. The company reported quarterly sales of $23.60 million which missed the analyst consensus estimate of $26.34 million by 10.40 percent. This is a 0.13 percent decrease over sales of $23.63 million the same period last year.